November 2022

Mobile health (mHealth) and a patient activation program could serve as a model for improving health outcomes for patients in outpatient clinical settings by decreasing atherosclerotic cardiovascular disease risk score.

Increased hospital mortality odds among non–COVID-19 patients imply compromised quality of care during COVID-19 surges. No large-scale changes were found in discharges to other facilities.

Findings suggest that Basaglar was not less expensive for patients than Lantus. Empirical evaluation of biosimilar costs prior to automatic substitution is necessary.

Prediction models combining claims data with social determinants of health and additional, more-timely data sources using artificial intelligence (AI) can better identify individuals with the highest future medical spending.

Efforts are needed to ensure that Medicare beneficiaries with poor mental health receive regular routine care, which may be facilitated by having a personal doctor.

The probability of drug interactions increases when genetic polymorphisms are considered, indicating that pharmacogenetic assessment may be useful in predicting the presence and severity of interactions.

Medicaid enrollees residing in counties with greater food affordability had lower odds of preventable hospitalization related to diabetes.

Few eligible individuals apply for the Advance Premium Tax Credit due to knowledge barriers. Additionally, specific sociodemographic characteristics appear to predict applying status.

This review describes the impact of nonmedical switching of biologic therapies on US patients and providers, with a focus on switching to in-class alternatives.

As we reset post pandemic, providers and payers are in an excellent position to prioritize a reallocation of health care expenditures driven primarily by individual and population health gains.

Use of low-value care services during COVID-19 exhibits substantial heterogeneity but, on average, shows declines similar to the use of high-value services; low-value care use lags behind high-value care use in the rebound phase.